NAVAN Technologies

Executive Summary

NAVAN Technologies is a private biotechnology company based in Cambridge, MA, developing a proprietary non-perturbative cell delivery platform. Founded in 2018, the company's technology enables gentle and precise intracellular delivery of virtually any cargo—including nucleic acids, proteins, and gene editing components—into a wide range of primary cell types while maintaining high cell viability and functionality. This platform addresses a critical bottleneck in cell therapy and genetic medicine: efficient and safe delivery without compromising cell health. NAVAN's core capabilities include dosage control, multiplexing, and even cellular extraction or sampling, positioning it as a versatile tool for research and therapeutic applications. The company's initial focus is on oncology and cell therapy, where preserving cell fitness is paramount for effective treatments. As a private entity, NAVAN has not disclosed its funding history or valuation, but its innovative approach has the potential to enable next-generation cell therapies and accelerate drug development. However, the company faces competition from established delivery platforms and must demonstrate in vivo efficacy and scalability to attract strategic partnerships and financing.

Upcoming Catalysts (preview)

• Q4 2026Series B Financing Round70% success
• Q2 2027Partnership with Major Cell Therapy Developer60% success
• Q1 2027In Vivo Proof-of-Concept Data for mRNA Delivery75% success